Lindsay TAO｜陶立

Corporate Director, Global Health Policy ｜全球卫生政策总监

Johnson&Johnson｜强生

Lindsay Tao, M.D. is Corporate Director, Global Health Policy. In this role, she provides cross sector leadership in regulatory policy focusing on safety, quality and efficacy of medicinal products. Before she moved to current position in 2009, She was the Vice President of Strategic Medical Affairs, Johnson & Johnson Medical Greater China (including China, HK, Taiwan), responsible for regulatory, quality and compliance, clinical research & medical, health policy and government affairs.

Besides her role in J&J, she also represents healthcare industry and takes different roles in regional and global organizations, e.g. GHTS SG1, UDI ad hoc working group members, WHO medical device nomenclature expert group member, AHWP Vice Chair, APEC RHSC industry coalition alternative coordinator and etc. to promote international regulatory best practices and regulatory convergence.

Lindsay has over 27 years experience in healthcare industry. Before Join J&J, Lindsay worked in Schering-Plough and Bristol-Mayers Squibb, held positions of increasing responsibilities in regulatory and clinical research area.

Lindsay was trained as a clinical physician and worked as an Oncologist in Shanghai Cancer Hospital, Fu Dan University before she join corporation.

陶立， 美国强生公司全球卫生政策执行总监

负责美国强生公司全球卫生政策， 包括药品,和医疗器械的监管政策。 曾任强生医疗器械大中华区战略医学事务部副总裁，负责法规、医学、质量和政府事务。并担任医疗器械国际协调组织GHTF第一工作（上市前审批）小组、UDI工作小组成员， 亚洲法规协调组织AHWP副主席等职位。目前， 她代表强生公司和医药和医疗器械行业参加亚太经合组织，世界卫生组织， 国际标准化组织等一系列国际和区域的法规和标准的协调工作，积极推广基于国际最佳实践的全球法规协调。

陶立有超过27年的医药行业的工作经验， 在加入强生之前， 她在先灵葆雅和施贵宝从事药品注册和临床工作。